Avid Bioservices Inc (CDMO)

[biopharm]

Very interesting and what percent of the float was traded on those big up days...in first few trading days of July? Maybe Wayne Holman will put in a offer for Avid Bioservices since it would help Ridgeback Capital and Ridgeback Biotherapeutics

Other than that not adding up (unless manipulation to simply buy cheap shares ) then we have Axel Hoos that is oh so happy that Dr Jedd Wolchok was stopped from having Bavi combo push GSK OX40 out of the picture

Axel a big GSK guy and pushing OX40 etc
___

What did Axel Hoos want? He did not seem to want Dr Jedd Wolchok to highlight Bavituximab combo better than OX40...as Dr Wolchok publicly put forth...

______


Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma

Weiyi Peng,
Leila J. Williams,
Chunyu Xu,
Brenda Melendez,
Jodi A. McKenzie,
Yuan Chen,
Heather L. Jackson,
Kui S. Voo,
Rina M. Mbofung,
Sara Elizabeth Leahey,
Jian Wang,
Gregory Lizee,
Hussein A. Tawbi,
Michael A. Davies,
Axel Hoos,
James Smothers,
Roopa Srinivasan,
Elaine M. Paul,
Niranjan Yanamandra and
Patrick Hwu

DOI: 10.1158/1078-0432.CCR-19-1259

Published November 2019

Abstract

Purpose: OX40 agonist based combinations are emerging as a novel avenue to improve the effectiveness of cancer immunotherapy.
...
...

https://clincancerres.aacrjournals.org/content/25/21/6406

______

Next, we have Sabin Vaccine Institute help Holman ( after how much monies given? ) and the ties that will be coming are astronomical that will prove PS Targeting has always been the target ...

Remember, Wendy Commins Holman spouse is Wayne Holman ( SAC Steve Cohen tie) and Citadel has Brittany Commins and I wonder when John Springs Stafford comes clean and tells all what a mitake Ronin Capital made in painting a not so rosy picture for the IP assets help at Peregrine ...

___

https://www.sabin.org/updates/pressreleases/wendy-holman-joins-sabin-vaccine-institute-board-trustees

Wendy Holman Joins Sabin Vaccine Institute Board of Trustees


Wednesday, August 2, 2017
WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) is pleased to announce the election of Wendy Commins Holman to its Board of Trustees. Ms. Holman is the CEO and founder of Ridgeback Biotherapeutics, a biotechnology company focused on developing treatments and diagnostics for underserved patient populations primarily in pediatric orphan and emerging infectious diseases.

Prior to founding Ridgeback Biotherapeutics, Ms. Holman was a principal at Ziff Brothers Investments and director of research at ZBI Equities, a multi-billion dollar public equity investment fund where she spent 15 years guiding investments in healthcare and novel technology.

“We are very pleased to welcome Wendy to our board,” said Dr. Axel Hoos, chairman of Sabin’s Board of Trustees. “Her knowledge and experience of innovative technologies and deep interest in global health will be an important addition to the board as we advance our vision of a future free from vaccine-preventable diseases.”

The addition of Ms. Holman to the Board of Trustees comes as the Sabin Vaccine Institute has implemented a strategic plan and mission to make vaccines more accessible, enable innovation and expand immunization across the globe.

“I am delighted to join Sabin at such an opportune moment for the organization,” said Ms. Holman. “I look forward to supporting Sabin’s efforts to expand immunization and explore new scientific approaches to identify solutions with the potential to improve the lives of millions of people around the world.”

“It has been my privilege over the years to work with wonderful people and be able to assess and invest in health technology,” Ms. Holman said. “Now I am focused on bringing those solutions to everyone, regardless of where they were born. By championing immunization, we can have an immediate impact on human suffering. Every mother – every human being – should care about preventing disease and providing a healthy start for every child and every family.”

In addition to her role at Ridgeback Biotherapeutics, Ms. Holman serves as the campaign chair for the University of Pennsylvania’s new Biotech Commons and on the Penn Libraries Board of Overseers. She lives in Miami, FL with her husband and four children.




___

Cell surface receptors for phosphatidylserine contribute to the entry of Ebola virus (EBOV) particles, indicating that the presence of phosphatidylserine in the envelope of EBOV is important for the internalization of EBOV particles.

https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1006848

_____

Cohen has said in a deposition with the SEC that he decided to sell SAC Capital's position in Wyeth after speaking with Holman. Martoma's lawyers had sought to introduce the deposition at trial, but U.S. Judge Paul Gardephe denied the bid.


https://mobile.reuters.com/article/amp/idUSBREA0S04220140129

______

We recently demonstrated that a soluble protein, Gas6, can facilitate viral entry by bridging viral envelope phosphatidylserine to Axl, a receptor tyrosine kinase expressed on target cells. The interaction between phosphatidylserine, Gas6, and Axl was originally shown to be a molecular mechanism through which phagocytes recognize phosphatidylserine exposed on dead cells. Since our initial report, several groups have confirmed that Axl/Gas6, as well as other phosphatidylserine receptors, facilitate entry of dengue, West Nile, and Ebola viruses. Virus binding by viral envelope phosphatidylserine is now a viral entry mechanism generalized to many families of viruses. In addition to Axl/Gas6, various molecules are known to recognize phosphatidylserine; however, the effects of these molecules on virus binding and entry have not been comprehensively evaluated and compared. In this study, we examined most of the known human phosphatidylserine-recognizing molecules, including MFG-E8, TIM-1, -3, and -4, CD300a, BAI1, and stabilin-1 and -2, for their abilities to facilitate virus binding and infection. Using pseudotyped lentiviral vectors, we found that a soluble phosphatidylserine-binding protein, MFG-E8, enhances transduction. Cell surface receptors TIM-1 and -4 also enhance virus binding/transduction. The extent of enhancement by these molecules varies, depending on the type of pseudotyping envelope proteins. Mutated MFG-E8, which binds viral envelope phosphatidylserine without bridging virus to cells, but, surprisingly, not annexin V, which has been used to block phagocytosis of dead cells by concealing phosphatidylserine, efficiently blocks these phosphatidylserine-dependent viral entry mechanisms. These results provide insight into understanding the role of viral envelope phosphatidylserine in viral infection.
...
...
https://jvi.asm.org/content/jvi/88/8/4275.full.pdf

______


Ridgeback Biotherapeutics LP announces an update on mAb114, an experimental treatment for Ebola

....

To date, all funding for Ridgeback Biotherapeutics has originated from Wayne and Wendy Holman; two individuals committed to investing in and supporting technologies that will make the world a better place.
...

https://www.prnewswire.com/news-releases/ridgeback-biotherapeutics-lp-announces-an-update-on-mab114-an-experimental-treatment-for-ebola-300900098.html

____

PS regulates tumor immunity

Nov 20, 2019
https://investor.omeros.com/static-files/c0364b85-7862-4cfe-be63-d07508226ae4

Sept 10, 2019
https://investor.omeros.com/static-files/32f2f111-fc8f-47ec-b3ec-4a8a3ef931ac

https://investor.omeros.com/presentations